Revenue $25.31B, up 6.6% on a year earlier. Innovative Medicine Segment Sales $16.38B, up 7.8%. MedTech segment sales $8.93B, up 4.5%. Diluted EPS $2.27 against $2.29.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $25.31B | $24.06B | $23.74B | +6.6% |
| Net income | $5.53B | $5.24B | $5.54B | -0.1% |
| Diluted EPS | $2.27 | $2.14 | $2.29 | |
| Operating cash flow | $8.62B | $2.51B | $3.88B | +122.2% |
| Capital expenditures | -$1.32B | -$1.05B | -$1.04B | |
| Free cash flow | $7.29B | $1.47B | $2.83B | +157.3% |
| Dividend per share | $1.34 | $1.30 | $1.30 |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| Innovative Medicine Segment Sales | $16.38B | $15.20B | +7.8% |
| MedTech segment sales | $8.93B | $8.54B | +4.5% |
| Operational sales growth | 5.6% | 4.6% | |
| Adjusted operational sales growth | 5.7% | 3% | |
| Reported sales growth | 6.6% | 5.77% | |
| Stelara worldwide sales | $740.00M | $1.65B | -55.2% |
| XARELTO Worldwide Sales | $664.00M | $621.00M | +6.9% |
| IMBRUVICA Worldwide Sales | $599.00M | $735.00M | -18.5% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Johnson & Johnson (JNJ) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/JNJ/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
